BRIEF: Legend Biotech’s revenue rises 36% in second quarter
Drug maker Legend Biotech Corp. (LEGN.US) on Monday reported strong revenue growth in the second quarter of 2025 as its core cancer drug gained traction. But its net loss also…
BRIEF: Hutchmed’s revenue falls in first half of 2025
Drug maker Hutchmed (China) Ltd. (HCM.US; 0013.HK) reported its revenue fell in the first half of 2025, as a small gain for its best-selling drug failed to offset declines for…
BRIEF: Innogen launches $87 million Hong Kong IPO
Guangzhou Innogen Pharmaceutical Group Co. Ltd. (6603.HK) launched its Hong Kong IPO on Thursday, aiming to sell 36.56 million shares for HK$18.68 apiece to raise about HK$683 million ($87 million).…
BRIEF: YSB Inc.’s profit triples in first half of 2025
Pharmaceutical e-commerce platform YSB Inc. (9885.HK) announced on Thursday that it expects to record a net profit of 70 million yuan ($9.75 million) or more for the six months through…
BRIEF: WuXi AppTec raises $975 Million through share placement at 6.9% discount
Pharmaceutical outsourcing giant WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) announced on Thursday it will raise HK$7.65 billion ($975 million) by placing around 73.8 million new Hong Kong-listed shares at HK$104.27…
BRIEF: Yonghe Medical returns to the black in first half of 2025
Hair transplant company Yonghe Medical Group Co. Ltd. (2279.HK) on Tuesday said it returned to the black in the first half of 2025, adding it expects to report a net…
BRIEF: Leads Biolab nearly doubles in Hong Kong trading debut
Shares of Nanjing Leads Biolab Co. Ltd. (9887.HK) rose 91.7% to close at HK$67.10 on their first trading day on Friday, after the company sold 36.86 million shares for HK$35 each,…